评估重症患者静脉推注和静脉捎带头孢曲松的疗效。

IF 4.3 2区 医学 Q1 INFECTIOUS DISEASES Antibiotics-Basel Pub Date : 2024-09-26 DOI:10.3390/antibiotics13100921
Elly R Sherman, Nha Hue Ta, Trisha N Branan, Natt Patimavirujh, Luren Ashton Dickinson, Christopher M Bland, Susan E Smith
{"title":"评估重症患者静脉推注和静脉捎带头孢曲松的疗效。","authors":"Elly R Sherman, Nha Hue Ta, Trisha N Branan, Natt Patimavirujh, Luren Ashton Dickinson, Christopher M Bland, Susan E Smith","doi":"10.3390/antibiotics13100921","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objective</b>: Intravenous fluid shortages have led to fluid-sparing measures such as intravenous push (IVP) administration of antibiotics. This study aimed to compare the safety and efficacy of IVP and intravenous piggyback (IVPB) ceftriaxone in critically ill patients. <b>Results</b>: Demographics were similar in IVP (<i>n</i> = 201) and IVPB (<i>n</i> = 200) groups. Sequential Organ Failure Assessment (SOFA) score was higher, and sepsis and septic shock were more common in the IVP group. Treatment failure occurred in 37.8% of IVP and 19.5% of IVPB groups (<i>p</i> < 0.001). Hospital mortality was more common with IVP (21.4% vs. 9.5%, <i>p</i> < 0.001). Hospital LOS was longer with IVP while intensive care unit (ICU) LOS was similar between the groups. IVP ceftriaxone (OR 2.33, 95% CI 1.43-3.79) and the SOFA score (OR 1.18, 95% CI 1.1-1.27) were associated with treatment failure. <b>Methods</b>: A single-center, retrospective cohort study included adults admitted to an ICU from 2016 to 2021 who received empiric ceftriaxone for ≥72 h. The primary outcome was treatment failure, defined as a composite of inpatient mortality or escalation of antibiotics. Secondary outcomes included length of stay (LOS) and mortality. Chi-squared and independent-sample <i>t</i>-tests were used. Treatment failure was evaluated using multivariate logistic regression. <b>Conclusions</b>: Compared to IVPB, IVP ceftriaxone was associated with higher treatment failure in critically ill patients. Both safety and efficacy should be considered before implementing novel antibiotic administration strategies in practice based primarily on convenience.</p>","PeriodicalId":54246,"journal":{"name":"Antibiotics-Basel","volume":"13 10","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504261/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the Efficacy of Intravenous Push and Intravenous Piggyback Ceftriaxone in Critically Ill Patients.\",\"authors\":\"Elly R Sherman, Nha Hue Ta, Trisha N Branan, Natt Patimavirujh, Luren Ashton Dickinson, Christopher M Bland, Susan E Smith\",\"doi\":\"10.3390/antibiotics13100921\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background/Objective</b>: Intravenous fluid shortages have led to fluid-sparing measures such as intravenous push (IVP) administration of antibiotics. This study aimed to compare the safety and efficacy of IVP and intravenous piggyback (IVPB) ceftriaxone in critically ill patients. <b>Results</b>: Demographics were similar in IVP (<i>n</i> = 201) and IVPB (<i>n</i> = 200) groups. Sequential Organ Failure Assessment (SOFA) score was higher, and sepsis and septic shock were more common in the IVP group. Treatment failure occurred in 37.8% of IVP and 19.5% of IVPB groups (<i>p</i> < 0.001). Hospital mortality was more common with IVP (21.4% vs. 9.5%, <i>p</i> < 0.001). Hospital LOS was longer with IVP while intensive care unit (ICU) LOS was similar between the groups. IVP ceftriaxone (OR 2.33, 95% CI 1.43-3.79) and the SOFA score (OR 1.18, 95% CI 1.1-1.27) were associated with treatment failure. <b>Methods</b>: A single-center, retrospective cohort study included adults admitted to an ICU from 2016 to 2021 who received empiric ceftriaxone for ≥72 h. The primary outcome was treatment failure, defined as a composite of inpatient mortality or escalation of antibiotics. Secondary outcomes included length of stay (LOS) and mortality. Chi-squared and independent-sample <i>t</i>-tests were used. Treatment failure was evaluated using multivariate logistic regression. <b>Conclusions</b>: Compared to IVPB, IVP ceftriaxone was associated with higher treatment failure in critically ill patients. Both safety and efficacy should be considered before implementing novel antibiotic administration strategies in practice based primarily on convenience.</p>\",\"PeriodicalId\":54246,\"journal\":{\"name\":\"Antibiotics-Basel\",\"volume\":\"13 10\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504261/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibiotics-Basel\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/antibiotics13100921\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/antibiotics13100921","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:由于静脉输液短缺,人们采取了静脉推注(IVP)抗生素等节约输液的措施。本研究旨在比较重症患者静脉推注和静脉回输头孢曲松的安全性和有效性。研究结果IVP组(n = 201)和IVPB组(n = 200)的人口统计学特征相似。IVP组的序贯器官衰竭评估(SOFA)评分更高,脓毒症和脓毒性休克更常见。IVP组和IVPB组分别有37.8%和19.5%的患者出现治疗失败(P < 0.001)。IVP 组的住院死亡率更高(21.4% 对 9.5%,P < 0.001)。IVP组的住院时间更长,而两组重症监护室(ICU)的住院时间相似。静脉滴注头孢曲松(OR 2.33,95% CI 1.43-3.79)和 SOFA 评分(OR 1.18,95% CI 1.1-1.27)与治疗失败有关。研究方法一项单中心回顾性队列研究纳入了2016年至2021年期间入住ICU并接受经验性头孢曲松治疗≥72小时的成人。次要结果包括住院时间(LOS)和死亡率。采用卡方检验和独立样本 t 检验。采用多变量逻辑回归对治疗失败进行评估。得出结论:与 IVPB 相比,IVP 头孢曲松对重症患者的治疗失败率更高。在主要基于方便性的基础上实施新型抗生素给药策略之前,应同时考虑安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluation of the Efficacy of Intravenous Push and Intravenous Piggyback Ceftriaxone in Critically Ill Patients.

Background/Objective: Intravenous fluid shortages have led to fluid-sparing measures such as intravenous push (IVP) administration of antibiotics. This study aimed to compare the safety and efficacy of IVP and intravenous piggyback (IVPB) ceftriaxone in critically ill patients. Results: Demographics were similar in IVP (n = 201) and IVPB (n = 200) groups. Sequential Organ Failure Assessment (SOFA) score was higher, and sepsis and septic shock were more common in the IVP group. Treatment failure occurred in 37.8% of IVP and 19.5% of IVPB groups (p < 0.001). Hospital mortality was more common with IVP (21.4% vs. 9.5%, p < 0.001). Hospital LOS was longer with IVP while intensive care unit (ICU) LOS was similar between the groups. IVP ceftriaxone (OR 2.33, 95% CI 1.43-3.79) and the SOFA score (OR 1.18, 95% CI 1.1-1.27) were associated with treatment failure. Methods: A single-center, retrospective cohort study included adults admitted to an ICU from 2016 to 2021 who received empiric ceftriaxone for ≥72 h. The primary outcome was treatment failure, defined as a composite of inpatient mortality or escalation of antibiotics. Secondary outcomes included length of stay (LOS) and mortality. Chi-squared and independent-sample t-tests were used. Treatment failure was evaluated using multivariate logistic regression. Conclusions: Compared to IVPB, IVP ceftriaxone was associated with higher treatment failure in critically ill patients. Both safety and efficacy should be considered before implementing novel antibiotic administration strategies in practice based primarily on convenience.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Antibiotics-Basel
Antibiotics-Basel Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
7.30
自引率
14.60%
发文量
1547
审稿时长
11 weeks
期刊介绍: Antibiotics (ISSN 2079-6382) is an open access, peer reviewed journal on all aspects of antibiotics. Antibiotics is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology and pharmacology. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.
期刊最新文献
The Synergy of Machine Learning and Epidemiology in Addressing Carbapenem Resistance: A Comprehensive Review. Resilience of Loin Meat Microbiota and of Resistance Genes to a Chlortetracycline Treatment in Weaned Piglets. Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections. Combinations of Terminalia bellirica (Gaertn.) Roxb. and Terminalia chebula Retz. Extracts with Selected Antibiotics Against Antibiotic-Resistant Bacteria: Bioactivity and Phytochemistry. Isatin Bis-Imidathiazole Hybrids Identified as FtsZ Inhibitors with On-Target Activity Against Staphylococcus aureus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1